These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2305608)

  • 1. Azathioprine in the treatment of thyroid-associated ophthalmopathy.
    Perros P; Weightman DR; Crombie AL; Kendall-Taylor P
    Acta Endocrinol (Copenh); 1990 Jan; 122(1):8-12. PubMed ID: 2305608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.
    Perros P; Crombie AL; Matthews JN; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):367-72. PubMed ID: 8319368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Malignant ophthalmopathy. Results of corticosteroid therapy associated with a cytotoxic immunosuppressive agent].
    Aquino CS; Coelho JC; Tendrich M; Gonçalves Filho CA; Pinto JC; Pontes JP
    AMB Rev Assoc Med Bras; 1978 Apr; 24(4):115-8. PubMed ID: 308242
    [No Abstract]   [Full Text] [Related]  

  • 4. [Endocrine exophthalmos].
    Lavergne G; Winand R
    Bull Soc Belge Ophtalmol; 1973; 163(1):1-170. PubMed ID: 4351085
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy for the eye changes of Graves' disease.
    Burrow GN; Mitchell MS; Howard RO; Morrow LB
    J Clin Endocrinol Metab; 1970 Sep; 31(3):307-11. PubMed ID: 4916539
    [No Abstract]   [Full Text] [Related]  

  • 7. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.
    Hart RH; Kendall-Taylor P; Crombie A; Perros P
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):328-36. PubMed ID: 16117697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.
    Nishikawa M; Yoshimura M; Toyoda N; Masaki H; Yonemoto T; Gondou A; Kato T; Kurokawa H; Furumura T; Inada M
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):213-9. PubMed ID: 8105634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant agents in the treatment of Graves' ophthalmopathy.
    Bouzas EA; Karadimas P; Mastorakos G; Koutras DA
    Am J Ophthalmol; 2000 May; 129(5):618-22. PubMed ID: 10844053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postural variation of exophthalmometry in Graves' ophthalmopathy.
    Asad R; Tewari HK; Ahuja MM; Mithal A
    Indian J Ophthalmol; 1990; 38(4):166-8. PubMed ID: 2086467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Step-by-step treatment of progressive edematous-infiltrative ophthalmopathy in Graves' disease. Results of the first stage of treatment with glucocorticoids and glucocorticoids with azathioprine].
    Pilarska K; Czekalski S; Syrenicz A; Andrzejewska W; Krzystolik Z; Przerwa D; Daniel B
    Endokrynol Pol; 1988; 39(5):229-36. PubMed ID: 3076562
    [No Abstract]   [Full Text] [Related]  

  • 12. Intraocular pressure and proptosis in 95 patients with Graves ophthalmopathy.
    Ohtsuka K
    Am J Ophthalmol; 1997 Oct; 124(4):570-2. PubMed ID: 9323958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-lymphocyte-subsets in endocrine exophthalmos.
    Cenmamo G; Bizzarro A; Castello G
    Metab Pediatr Syst Ophthalmol (1985); 1985; 8(2-3):43-5. PubMed ID: 3879963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
    Kendall-Taylor P; Crombie AL; Stephenson AM; Hardwick M; Hall K
    BMJ; 1988 Dec; 297(6663):1574-8. PubMed ID: 2906260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of increased intraocular pressure on upgaze in the assessment of Graves ophthalmopathy.
    Spierer A; Eisenstein Z
    Ophthalmology; 1991 Oct; 98(10):1491-4. PubMed ID: 1961632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Graves' ophthalmopathy treated with azathioprine].
    Rørdam P; Larsen S; Helin P
    Ugeskr Laeger; 1986 May; 148(19):1157-8. PubMed ID: 3755262
    [No Abstract]   [Full Text] [Related]  

  • 19. [A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease].
    Bałdys-Waligórska A; Kuśnierz-Cabala B; Huszno B
    Endokrynol Pol; 2006; 57(5):536-40. PubMed ID: 17133319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy.
    Bufalo NE; Dos Santos RB; Marcello MA; Piai RP; Secolin R; Romaldini JH; Ward LS
    J Endocrinol Invest; 2015 May; 38(5):555-61. PubMed ID: 25543543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.